Observational Study
Copyright ©The Author(s) 2021.
World J Gastrointest Oncol. Jun 15, 2021; 13(6): 600-611
Published online Jun 15, 2021. doi: 10.4251/wjgo.v13.i6.600
Table 1 Demographic and clinical characteristics of the three study groups


HCC group
Cirrhosis group
Control group
P value
GenderMale301720> 0.05
Female101310
Age (years)mean (SD)60.07 ± 5.3458.33 ± 8.0755.2 ± 7.6> 0.05
Range50-6837-67 34-62
Child-Pugh score, n (%)A24 (60.0)19 (63.3)Not applicable
B11 (27.5)8 (26.7)Not applicable
C5 (12.5)3 (10.0)Not applicable
Table 2 Biomarker levels in the three study groups
HCC group
Cirrhosis group
Control group
P value
Mean
SD
Median
Mean
SD
Median
Mean
SD
Median
AFP (ng/mL)694.6885.38169.529.7138.7112.9523.5832.159.5< 0.0011
VEGF (pg/mL)1409917.401250233.3196.51150204190.89110< 0.0011
VEGF/PLT13.210.4210.641.681.401.180.950.710.72< 0.0011
Table 3 Diagnostic performance of alpha fetoprotein, vascular endothelial growth factor, and vascular endothelial growth factor/platelet, separately and in combination, in the prediction of hepatocellular carcinoma

Cut-off point
AUC
Sensitivity
Specificity
Accuracy
PPV
NPV
P value
AFP400.75465.0083.3374.17%72.278.1< 0.0001
VEGF2500.85980.0081.6780.8474.486.0< 0.0001
VEGF/PLT2.310.84277.5080.0078.7572.184.2< 0.0001
Combination --0.95392.5098.3395.4297.495.2< 0.0001
Table 4 Correlations between tumor characteristics (tumor size and stage) and each of alpha fetoprotein, vascular endothelial growth factor and vascular endothelial growth factor/ platelet among hepatocellular carcinoma cases

AFP (ng/mL)
VEGF (pg/mL)
VEGF/PLT
Size of tumorCorrelation coefficient0.4920.6620.483
P value0.0010.00010.002
TNM stage of tumorCorrelation coefficient0.2470.7950.696
P value0.1240.00010.0001
BCLC stage of tumorCorrelation coefficient0.3820.8890.740
P value0.0150.00010.0001
Table 5 Correlations between the presence of portal vein thrombosis and each of serum alpha fetoprotein, vascular endothelial growth factor, and vascular endothelial growth factor/platelet levels among hepatocellular carcinoma cases
No PVT
PVT
Independent t-test
Mean
SD
Mean
SD
t-value
P value
AFP (ng/mL)580.64854.691143.63923.42−1.6410.109
VEGF (pg/mL)1231.56907.972056.25661.94−2.4040.021
VEGF/PLT11.359.9820.859.12−2.4460.019
Table 6 Correlation between serum vascular endothelial growth factor and platelet count among the three study groups
VEGF
HCC group
CLC group
Control group
r
P value
r
P value
r
P value
Platelets 0.66810.002-0.00710.9700.05310.781
Table 7 Correlation between serum alpha fetoprotein and vascular endothelial growth factor levels among hepatocellular carcinoma cases
AFP (ng/mL)
r
P value
VEGF (pg/mL)0.1190.4631
Table 8 Correlation between serum alpha fetoprotein and vascular endothelial growth factor/platelet levels among hepatocellular carcinoma cases
AFP (ng/mL)
r
P value
VEGF/PLT0.1750.2801
Table 9 Positive correlation between serum vascular endothelial growth factor; and vascular endothelial growth factor/platelet levels among hepatocellular carcinoma cases
VEGF (pg/mL)
r
P value
VEGF/PLT0.9250.0001